Pioglitazone does not affect the risk of ovarian cancer: Analysis of a nationwide reimbursement database in Taiwan

Gynecologic Oncology

Volumn 131, Issue 1, 2013, Pages 135-139

  Tseng, Chin Hsiao ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Diabetes mellitus; Incidence density; Ovarian cancer; Pioglitazone; Taiwan

Indexed keywords

INSULIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY CANCER; PRIORITY JOURNAL; REIMBURSEMENT; TAIWAN; TREATMENT DURATION;

EID: 84885303854     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.07.087     Document Type: Article

References (29)

1. Arcidiacono B, Iiritano S, Nocera A, Possidente K, NevoloMT, Ventura V, et al. Insulin resistance and cancer risk: an overviewof the pathogeneticmechanisms. Exp Diabetes Res 2012;2012:789174.
2. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90: 1774-86.
3. King ER, Zu Z, Tsang YT, Deavers MT, Malpica A, Mok SC, et al. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecol Oncol 2011;123: 13-8.
4. Attias-Geva Z, Bentov I, Fishman A, Werner H, Bruchim I. Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines. Gynecol Oncol 2011;121: 383-9.
5. Tseng CH, Tseng FH. Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2012;30: 368-402.
6. Nicol CJ, Yoon M,Ward JM, Yamashita M, Fukamachi K, Peters JM, et al. PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis 2004;25: 1747-55.
7. Shigeto T, Yokoyama Y, Xin B, Mizunuma H. Peroxisome proliferator- activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer. Oncol Rep 2007;18: 833-40.
8. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry Jr CP, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011;34: 916-22.
9. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366: 1279-89.
10. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356: 2457-71.
11. Tseng CH. Diabetes and risk of prostate cancer: A study using the National Health Insurance. Diabetes Care 2011;34: 616-21.
12. Tseng CH. Diabetes and risk of bladder cancer: A study using the National Health Insurance database in Taiwan. Diabetologia 2011;54: 2009-15.
13. Katsiki N, Hatzitolios AI. Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update. Curr Opin Obstet Gynecol 2010;22: 466-76.
14. Al-Alem L, Southard RC, Kilgore MW, Curry TE. Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner. PLoS One 2011;6:e16179.
15. Rattan R, Giri S, Hartmann LC, Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 2011;15: 166-78.
16. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol 2011;123: 200-4.
17. Lee JY, Jeon I, Kim JW, Song YS, Yoon JM, Park SM. Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies. Int J Gynecol Cancer 2013;23: 402-12.
18. Brinton LA, Sakoda LC, Frederiksen K, Sherman ME, Kjaer SK, Graubard BI, et al. Relationships of uterine and ovarian tumors to pre-existing chronic conditions. Gynecol Oncol 2007;107: 487-94.
19. Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO. Diabetes mellitus and ovarian cancer (Sweden). Cancer Causes Control 2002;13: 759-64.
20. Lambe M, Wigertz A, Garmo H, Walldius G, Jungner I, Hammar N. Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes Control 2011;22: 1163-71.
21. Gapstur SM, Patel AV, Diver WR, Hildebrand JS, Gaudet MM, Jacobs EJ, et al. Type II diabetes mellitus and the incidence of epithelial ovarian cancer in the cancer prevention study-II nutrition cohort. Cancer Epidemiol Biomarkers Prev 2012;21: 2000-5.
22. Bakhru A, Buckanovich RJ, Griggs JJ. The impact of diabetes on survival in women with ovarian cancer. Gynecol Oncol 2011;121: 106-11.
23. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol 2012;23: 1771-80.
24. Kellenberger LD, Bruin JE, Greenaway J, Campbell NE, Moorehead RA, Holloway AC, et al. The role of dysregulated glucose metabolism in epithelial ovarian cancer. J Oncol 2010;2010:514310.
25. King MG, Olson SH, Paddock L, Chandran U, Demissie K, Lu SE, et al. Sugary food and beverage consumption and epithelial ovarian cancer risk: a population-based case- control study. BMC Cancer 2013;13:94.
26. Riman T, Nilsson S, Persson IR. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 2004;83: 783-95.
27. Lamkin DM, Spitz DR, Shahzad MM, Zimmerman B, Lenihan DJ, Degeest K, et al. Glucose as a prognostic factor in ovarian carcinoma. Cancer 2009;115: 1021-7.
28. Cheng TM. Taiwan's new national health insurance program: genesis and experience so far. Health Aff (Millwood) 2003;22: 61-76.
29. Attner B, Landin-Olsson M, Lithman T, Noreen D, Olsson H. Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden. Cancer Causes Control 2012;23: 769-77.